Efforts to find treatments for Alzheimer’s disease suffered blows in recent days, but many companies, scientists and investors are still optimistic that they can find a way to treat the memory-robbing disease, which affects roughly 5.5 million Americans.
Axovant Sciences Ltd. on Monday shuttered development for a once-promising Alzheimer’s drug, an announcement that came days after Pfizer Inc. said it was giving up on the space entirely. 
...  